Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$21.51 USD
-0.90 (-4.02%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $21.51 0.00 (0.00%) 7:04 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
Intellia Therapeutics, Inc. [NTLA]
Reports for Purchase
Showing records 141 - 160 ( 291 total )
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q21: Additional Data From Lead Program in 1Q22
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FDA Grants Orphan Drug Designation for NTLA-2001, Intellia?s Investigational Therapy for ATTR
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Data Showcases Intellia?s Potential Safety and Efficacy Edge Over Competition
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Early Animal Proof of Concept Data For Gene Therapy Presented
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
NTLA Flexing Its Gene Editing Platform at ESGCT
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Collaboration with SparingVision to Develop Ocular Therapies
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Intellia Enters Ocular Diseases Realm With Strategic Collaboration Agreement With SparingVision
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
NTLA''s New Collaboration Could Spare Vision
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Intellia Receives Authorization to Begin Phase 1/2 trial of NTLA-2002 for Treatment of Hereditary Angioedema (HAE)
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TCR Trial Posted on clinicaltrials.gov for AML
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Intellia Announces IND Acceptance For NTLA-5001, Its First CRISPR/Cas9 Engineered TCR T-Cell Therapy Candidate
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways from Fireside Chat with Genome Editing Powerhouse Intellia; Poised to Round off Catalyst Rich Year
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M